LSE$GSK
GlaxoSmithKline · Q3 2013 earnings
Q3 2013 earnings · · Investor relations
Headline financials
Revenue & EPS history
GSK · Revenue · Quarterly
£10.1B
Q3 2013
Revenue by segment
GSK · £7.63B total across 3 segments · Q4 2026
- Specialty Medicines£3.23B—42.3%
- General Medicines£2.25B—29.5%
- Vaccines£2.15B—28.2%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
+0.1%
Avg return
Earnings day
-0.2%
Avg return
5 days after
+0.4%
Avg return
30 days after
56%
28 / 50 earnings
Positive
+7.7%
Q4 2026
Best reaction
-9.6%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.3% | — | — | |
| Q4 2026 | +7.7% | -0.9% | -13.6% | |
| Q3 2025 | +6.4% | +6.1% | +9.5% | |
| Q2 2025 | +4.5% | +0.8% | +7.3% | |
| Q1 2025 | +2.3% | -3.3% | -4.5% | |
| Q4 2024 | +4.4% | +3.6% | +6.4% | |
| Q3 2023 | -4.3% | -2.8% | +6.8% | |
| Q4 2023 | +3.9% | +6.3% | +7.5% | |
| Q2 2023 | +0.5% | +3.9% | -4.8% | |
| Q1 2023 | -2.4% | -5.1% | -2.8% | |
| Q4 2022 | -0.4% | +0.2% | -1.7% | |
| Q3 2022 | -1.9% | -4.5% | +5.6% | |
| Q2 2022 | +1.0% | +1.2% | +10.0% | |
| Q1 2022 | +3.0% | -1.0% | -3.1% | |
| Q4 2021 | -1.7% | -5.2% | -10.3% | |
| Q3 2021 | +4.8% | +6.0% | +2.1% | |
| Q2 2021 | +1.5% | -0.2% | +10.8% | |
| Q1 2021 | -0.6% | +0.2% | -0.1% | |
| Q4 2020 | -5.9% | -0.9% | +5.2% | |
| Q3 2020 | -3.9% | -2.7% | +4.9% | |
| Q2 2020 | -2.5% | -0.0% | -4.1% | |
| Q1 2020 | -0.0% | +0.5% | -1.2% | |
| Q4 2019 | -6.3% | +6.0% | +10.1% | |
| Q3 2019 | +2.7% | +1.0% | +2.0% | |
| Q2 2019 | +0.5% | -1.6% | +7.3% | |
| Q1 2019 | -1.6% | -1.5% | -6.1% | |
| Q4 2018 | +2.8% | -2.3% | -3.4% | |
| Q3 2018 | +0.2% | +1.1% | +5.7% | |
| Q2 2018 | -2.1% | -1.5% | +4.6% | |
| Q1 2018 | -1.1% | -1.3% | -1.9% | |
| Q4 2017 | +0.5% | +0.8% | +3.8% | |
| Q3 2017 | -9.6% | -9.4% | -13.4% | |
| Q2 2017 | -2.9% | +0.0% | -10.8% | |
| Q1 2017 | -1.7% | -2.6% | -6.8% | |
| Q4 2016 | +1.4% | +1.3% | +4.8% | |
| Q3 2016 | +0.2% | -0.8% | -3.6% | |
| Q2 2016 | +2.3% | -0.4% | -8.4% | |
| Q1 2016 | +1.5% | — | — | |
| Q4 2015 | +0.2% | — | — | |
| Q3 2015 | +2.5% | — | — | |
| Q2 2015 | +4.5% | — | — | |
| Q1 2015 | -3.0% | — | — | |
| Q4 2014 | +3.8% | — | — | |
| Q3 2014 | +4.0% | — | — | |
| Q2 2014 | -5.9% | — | — | |
| Q1 2014 | -1.8% | — | — | |
| Q4 2013 | +2.8% | — | — | |
| Q3 2013 | -0.0% | — | — | |
| Q2 2013 | +0.8% | — | — | |
| Q1 2013 | +1.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro